Kirman C R, Sweeney L M, Teta M J, Sielken R L, Valdez-Flores C, Albertini R J, Gargas M L
The Sapphire Group, Inc., Cleveland, OH 44122, USA.
Risk Anal. 2004 Oct;24(5):1165-83. doi: 10.1111/j.0272-4332.2004.00517.x.
Ethylene oxide (EO) has been identified as a carcinogen in laboratory animals. Although the precise mechanism of action is not known, tumors in animals exposed to EO are presumed to result from its genotoxicity. The overall weight of evidence for carcinogenicity from a large body of epidemiological data in the published literature remains limited. There is some evidence for an association between EO exposure and lympho/hematopoietic cancer mortality. Of these cancers, the evidence provided by two large cohorts with the longest follow-up is most consistent for leukemia. Together with what is known about human leukemia and EO at the molecular level, there is a body of evidence that supports a plausible mode of action for EO as a potential leukemogen. Based on a consideration of the mode of action, the events leading from EO exposure to the development of leukemia (and therefore risk) are expected to be proportional to the square of the dose. In support of this hypothesis, a quadratic dose-response model provided the best overall fit to the epidemiology data in the range of observation. Cancer dose-response assessments based on human and animal data are presented using three different assumptions for extrapolating to low doses: (1) risk is linearly proportionate to dose; (2) there is no appreciable risk at low doses (margin-of-exposure or reference dose approach); and (3) risk below the point of departure continues to be proportionate to the square of the dose. The weight of evidence for EO supports the use of a nonlinear assessment. Therefore, exposures to concentrations below 37 microg/m3 are not likely to pose an appreciable risk of leukemia in human populations. However, if quantitative estimates of risk at low doses are desired and the mode of action for EO is considered, these risks are best quantified using the quadratic estimates of cancer potency, which are approximately 3.2- to 32-fold lower, using alternative points of departure, than the linear estimates of cancer potency for EO. An approach is described for linking the selection of an appropriate point of departure to the confidence in the proposed mode of action. Despite high confidence in the proposed mode of action, a small linear component for the dose-response relationship at low concentrations cannot be ruled out conclusively. Accordingly, a unit risk value of 4.5 x 10(-8) (microg/m3)(-1) was derived for EO, with a range of unit risk values of 1.4 x 10(-8) to 1.4 x 10(-7) (microg/m3)(-1) reflecting the uncertainty associated with a theoretical linear term at low concentrations.
环氧乙烷(EO)已被确定为实验动物中的致癌物。尽管确切的作用机制尚不清楚,但暴露于环氧乙烷的动物体内的肿瘤被认为是由其基因毒性导致的。已发表文献中大量流行病学数据得出的关于致癌性的总体证据权重仍然有限。有一些证据表明环氧乙烷暴露与淋巴/造血系统癌症死亡率之间存在关联。在这些癌症中,两个随访时间最长的大型队列提供的证据对于白血病最为一致。结合在分子水平上已知的人类白血病和环氧乙烷的情况,有一系列证据支持环氧乙烷作为潜在白血病致癌物的合理作用模式。基于对作用模式的考虑,从环氧乙烷暴露到白血病发生(进而导致风险)的一系列事件预计与剂量的平方成正比。为支持这一假设,二次剂量反应模型对观察范围内的流行病学数据提供了最佳的总体拟合。基于人和动物数据进行癌症剂量反应评估时,使用了三种不同的低剂量外推假设:(1)风险与剂量呈线性比例;(2)低剂量时不存在明显风险(暴露边际或参考剂量方法);(3)低于出发点的风险继续与剂量的平方成正比。环氧乙烷的证据权重支持使用非线性评估。因此,暴露于浓度低于37微克/立方米的环境中不太可能对人群造成明显的白血病风险。然而,如果需要对低剂量风险进行定量估计并考虑环氧乙烷的作用模式,这些风险最好使用癌症效力的二次估计值进行量化,与环氧乙烷癌症效力的线性估计值相比,使用替代出发点时,二次估计值低约3.2至32倍。描述了一种将选择合适的出发点与对所提出作用模式的置信度联系起来的方法。尽管对所提出的作用模式有很高的置信度,但不能完全排除低浓度下剂量反应关系中存在小的线性成分。因此,得出环氧乙烷的单位风险值为4.5×10⁻⁸(微克/立方米)⁻¹,单位风险值范围为1.4×10⁻⁸至1.4×10⁻⁷(微克/立方米)⁻¹,反映了与低浓度下理论线性项相关的不确定性。